|
Cancer Monthly News and CancerWire
|
|
|
|
|
Greetings!
Why are toxic drugs the continual focus of
conventional cancer
therapy despite the fact that so little progress has
been made in treating advanced and metastatic solid
cancers in the last 50 years?
In this edition of
CancerWire we focus on the conventional paradigm -
how the cancer industry approaches the treatment of
cancer. We begin with a fascinating article about the
esteemed
physician and researcher Dr. Andrew Ivy and what
happened to him after he discovered a potential cure
for cancer from an unlikely source - the blood of
horses. We will also look at current alternative and
complementary clinical trials for cancer and highlight
the few that address survival. And finally, we review
the approval of the expensive new drug Avastin
for breast cancer despite the fact that it did not
improve survival in the patients tested.
Disclaimer - Please Read: None of
the information in CancerWire is a
substitute for professional medical advice,
examination, diagnosis or treatment and you
should always seek the advice of your
physician or other qualified health
professional before starting any new
treatment or making any changes to an
existing treatment. No information contained
in Cancer Monthly or CancerWire including the
information below, should be used to
diagnose, treat, cure or prevent any disease
without the supervision of a medical
doctor.
|
Paradigm - A Way of Looking at Cancer
|
|
A paradigm is defined as a thought pattern in any
scientific discipline or a way of looking at the world.
In the context of conventional medicine and cancer
there is a very well defined paradigm. It can be
described as:
Cancer is caused by personal choices, genetics
and acts of God. Scientists around the country are
making important discoveries that are getting us
closer to a cure every day, but more money and
research is needed. When it comes, a cure for
cancer will come from a large pharmaceutical
company. Only a deeply researched expensive drug
can cure cancer. Anyone who is serious about
alternative or nutrition-based therapies is ill advised, a
multi-level marketer, or a quack. Alternative therapies
are ineffective, unproven or disproven and a waste of
money.
Of course, there are cancer survivors who feel they
owe their lives to various alternative therapies and
would beg to differ with the conventional paradigm.
And there are also innovative and open-minded
physicians that believe that there is more to cancer
treatment than the latest FDA approved drug.
Nonetheless, this paradigm has been with us for
decades and continues to dictate to a large degree
what is available to cancer patients and how drugs
are approved. In this edition of CancerWire we
examine the paradigm from three aspects: historical,
research, and regulatory.
|
|
Professor Andrew C. Ivy, M.D.
|
|
Esteemed Physician and the Cancer-Krebiozen Saga
Most people have never heard the name of Dr. Andrew
Ivy. He was a highly respected doctor who received an
enormous number of accolades over his
distinguished career. Yet, in the 1950's he became
involved in a cancer treatment called "krebiozen" and
within a short time his reputation was challenged.
Was Dr. Ivy onto something or was he unfairly
criticized? Here are some more details:
Professor Andrew C. Ivy, M.D. enjoyed an impeccable
reputation as a researcher, scientist and physician.
(1)
He taught thousands of medical students, had been
involved in over 1,300 medical studies, and had
discovered several of the body's hormones.(2) He
was
President of the American Gastroenterological
Association in 1940. In 1946, he was appointed as
the sole Medical Scientific Consultant to the U.S.
Military Tribunal No. 1 at Nuremberg to serve as "an
expert witness on scientific and ethical subjects."(3)
After the war, Ivy became the vice-president of the
University of Illinois where he ran that university's
large medical school.(4) He was also named
Executive
Director of the National Advisory Cancer Council and a
director of the American Cancer Society.(5) Dr. Ivy
also
received many honors including: five honorary Doctor
of Science degrees, one honorary Doctor of Law
degree, the Distinguished Alumni Award of the
University of Chicago, and The Certificate of Merit from
the President of the United States. Dr. Ivy's name can
be found in most standard medical dictionaries.(6)
For over twenty years, Ivy taught his medical students
that rare spontaneous remissions of cancer found in
the medical literature indicated the existence of some
chemical substance produced in the body which acts
as a defender against this disease.(7)
In 1949, Ivy began testing a cancer treatment called
krebiozen.(8) Invented by Dr. Stevan Durovic, (9)
krebiozen
was made from a hormone that horses generated
when they had been exposed to a fungus
(Actinomyces bovis) that caused a cancer-like
disease called "lumpy jaw."(10) The results of the
therapy
were very encouraging. Reportedly, the first terminal
cancer patients found their tumors disintegrating after
being administered the experimental drug.(11) In
1954,
Dr. Ivy collated, analyzed and evaluated the various
reports from physicians who had used krebiozen on
terminal cancer patients. A summary of this medical
report indicated, "In 111 of 226 externally measurable
cases, or in about 50% of these cases, the tumors
decreased in size."(12)
Rather than represent the start of a new direction in
treating cancer, these observations were rejected by
the medical establishment. In rapid succession
after his involvement with krebiozen, Dr. Ivy was
suspended from membership in the Chicago Medical
Society, removed from the vice presidency of the
University of Illinois, and had his resignation accepted
by the National Advisory Cancer Council and the
American Cancer Society. In addition, his work with
krebiozen was assailed as inaccurate and
unscientific. Apparently his methods which had been
good enough to earn him a worldwide reputation were
suddenly wrong.
The FDA never approved krebiozen.(13) At least two
lawsuits (one brought by a patient and one brought by
another physician) attempted to make this drug
accessible, but failed. In both cases the courts
decided that the FDA was in the best position to
determine whether krebiozen should be accessible or
not.
At the time the United States government was
outlawing krebiozen, it was widely accepted amongst
orthodox medicine that human beings possessed no
specific resistance to cancer in their blood. Hence, the
notions that a substance from the blood of horses
could arrest or cure cancer in people sounded like
quackery to government scientists.
Today, Drs. Ivy's insights may be better appreciated. In
the last 20 years, mainstream science may have
caught up with the insights of this physician.
According to a leading medical treatise, "Animal
studies have conclusively shown that the immune
system can recognize and eliminate malignant
tumors in vivo."(14) In recent years, billions of
dollars
have been invested in isolating and synthesizing
interleukin, interferon, and other cytokines-all natural
immune-related substances which can kill or arrest
cancer and that are found in the blood of mammals
including horses and man.
End Notes
1) For partial biographical material please see: The
American Physiological Society, 17th APS President
(1939-1941), Andrew C. Ivy, (1893-1978), at
http://www.the-
aps.org/about/pres/introaci.htm
2) HERBERT BAILEY, A MATTER OF LIFE OR DEATH
28-29 (1958).
3) ALEXANDER MITSCHERLICH & FRED MIELKE,
DOCTORS OF INFAMY, THE STORY OF THE NAZI
MEDICAL CRIMES IX (1949). "[T]he [U.S.] Secretary of
War asked the Board of Trustees of the American
Medical Association [AMA] to nominate a medical
scientist to serve as a consultant to the Nuremberg
trial of Nazi physicians." From the tens of thousands of
AMA physicians, this organization chose Dr. Ivy.
4) BAILEY, supra note 2, at 28-29.
5) Id. at 30.
6) DORLAND'S ILLUSTRATED MEDICAL
DICTIONARY 1611 (25th ed. 1974). Ivy invented a test
he used to measure platelet and capillary function. Id.
7) BAILEY, supra note 2, at 31.
8) The word "Krebiozen" was compounded from
Greek terms meaning "that which regulates growth."
BAILEY, supra note 2, at 38-39.
9) Durovic was a Yugoslav refugee who had been
living in Buenos Aires. Id. at 10. He had worked at the
Pasteur Institute in Paris prior to WWII. BAILEY, supra
note 2, at 16.
10) Id. at 22.
11) Id. at 39-43.
12) HERBERT BAILEY, KREBIOZEN-KEY TO
CANCER? 300 (1955).
13) Tutoki v. Celebrezze, 375 F.2d 105, 107 (7th Cir.
1967).
14) HARRISON'S PRINCIPLES OF INTERNAL
MEDICINE 535 (Anthony S. Fauci, et al. eds., 14th ed.
1998).
|
|
Clinical Trials and Alternative Treatments
|
|
Small Number of Clinical Trials Focus on Alternative Approaches
The conventional paradigm that a viable treatment for
cancer will come from a toxic synthesized drug and
not an alternative non-toxic remedy is reflected in how
our
research dollars are spent. For example, there are
thousands of cancer clinical trials. Many of these are
funded or partially funded by our tax dollars through
the National Cancer Institute (NCI). Others are funded
wholly by pharmaceutical companies, foundations,
and medical
centers. Cancer Monthly recently performed a cursory
analysis to determine which and how many clinical
trials are focused on alternative or complementary
therapies. The results were disappointing, but not
surprising.
According to the NCI database there are currently
7,080 active clinical trials for cancer. A review of these
trials found nearly half were focused on chemotherapy
and over two thousand looked at cutting edge
biological
therapies like anti-angiogenesis approaches such as
Veglin. Many of these biological therapies apply
our latest understanding of genetics and the
biological basis of cancer and no doubt reflect a
quantum leap from the indiscriminate toxicity of
chemotherapy. Nonetheless, only 123 trials
were "complementary or
alternative" - treatments focused on naturally
occurring agents.
These 123 represent only 1.7% of the total and
included trials of various foods, herbs and modalities
such as: soy, ginger, Valerian, Curcumin,
acupuncture, Reiki, meditation, garlic, Green tea, and
Tai Chi. At first glance, this is encouraging. A more
thorough analysis, however, revealed that the
overwhelming majority of these trials examined
questions that did not focus on whether these
approaches alone improved survivability from cancer.
The breakdown revealed:
Most of these categories are self explanatory with the
possible exception of Dr. Stanislaw Burzynski's
antineoplastons. These 24 trials are "alternative or
complementary" in the sense that this is an original
modality not taught in U.S. medical schools and not
generally available in U.S. hospitals. The constituents
of antineoplastons include natural components and
sodium phenylbutyrate, arguably a drug. Dr. Burzynski
has had some success especially with aggressive
brain cancers and his clinical trials focus on survival
as one of the primary outcome measures.
The three additional clinical trials that focused on
improving survival included:
1. Sun's Soup in lung cancer - this trial
compares the survival of patients with stage IIIB or IV
non-small cell lung cancer receiving selected
vegetables (Sun's soup dietary supplement vs
placebo). Sun's soup consists of 19 vegetable and
herbs in a highly concentrated form. According to
information on this trial, "These vegetables and herbs
were selected based on their anti-cancer and
immune-enhancing activities." (Trial # NCT00246727)
2. Green tea in leukemia - this phase I/II
study of green tea extract (Polyphenon E) focuses on
patients with previously untreated stage 0-II chronic
lymphocytic leukemia (Trial # NCT00262743)
3. Fruits and vegetables for head & neck
cancer - this randomized phase II trial is studying how
well fruit and vegetable extracts work in preventing the
recurrence of stage I, stage II, stage III, stage IVA, or
stage IVB head and neck cancer. (Trial #
NCT00064298)
Therefore if one includes Dr. Burzynski's
antineoplaston studies, a total of 27 clinical trials out
of 7,080, less than half of one percent are focused on
alternative and complementary therapies as a stand
alone treatment to assess survival. If one considers
the Burzynski trials as a separate category, then only 3
of 7,080 or .04% are focused on this question.
These numbers speak volumes. Alternative therapies
represent a small minority of cancer clinical trials and
only a smaller number of these are focused on
whether they are viable treatments. While there were
3,198 chemotherapy trials, a treatment that has been
experimented with for over fifty years, less than 30
trials were focused on natural approaches.
This analysis suggests what many observers have
been reporting for some time that alternative
therapies - stand alone natural cancer treatments
have been co-opted into the conventional paradigm.
They are no
longer seen as potentially powerful treatments in their
own right, but rather "add-ons" to ameliorate the side
effects or improve the quality of life for patients who
receive the toxic conventional treatments.
|
|
FDA Approves Cancer Drug Despite No Increase in Survival
|
|
Taking the conventional paradigm to its logical
eextreme we get the
recent FDA approval of Avastin for breast cancer. The
FDA actually approved an expensive and toxic cancer
drug that does not improve the survival of the patients
who take it.
You have seen the headlines - "Genentech Shares
Jump on FDA Avastin Nod," "Genentech shares soar
after FDA action," "Genentech rockets on FDA approval
for Avastin." After the FDA approved Avastin for breast
cancer, the stock for the biotech company Genentech
jumped over 10%. According to some analysts this
approval may add over $500 million in sales. Other
estimates are over one billion dollars in three years.
A review of the transcript of the FDA's own Oncologic
Drugs Advisory Committee suggests a number of
unsettling aspects, including:
· Survival - The drug did not increase overall survival
in the breast cancer patients tested.
· Toxicity - More patients died toxic deaths who
received Avastin in combination with paclitaxel than
those who received paclitaxel alone. In addition there
were more life threatening adverse events (side
effects) in those breast cancer patients who received
Avastin.
· Problems With the Clinical Trial that Led to Approval -
There were a number of issues with the clinical trial
highlighted by the FDA including lack of data, the
subjective nature of the findings, missing information,
and protocol violations.
· Committee Voted "No" on Approval - The FDA's own
Oncologic Drugs Advisory Committee voted not to
approve Avastin for breast cancer 5-4. Inexplicably,
FDA bureaucrats overturned the decision of its own
Advisory Committee.
|
|
Challenging Paradigms
|
|
Paradigms by themselves are not bad.
But a false paradigm especially in the context of a life
threatening disease like cancer, can be exceedingly
dangerous. Nonetheless, even when paradigms are
demonstrated to be false again and again, the status
quo may not change.
For example, in the mid 1800's, after much
observation and analysis, the
Austro-Hungarian physician Semmelweis concluded
that more women were dying when attended on the
physician and medical student ward, versus those
attended by midwives.
According to the website "
RationalWiki" "Semmelwies developed several
hypotheses to test, among them that doctors and
medical students some how passed "particles" of
disease to patients. Semmelweis noted that doctors
and medical students would perform autopsies, then
go to the ward to deliver babies, one after the other.
Midwives did not. He posited that particles of illness
were making mothers ill, and that washing hands
might prevent illness. He tested this by instituting a
strict regimen of hand washing with a chlorine-lime
solution before examining mothers or delivering
babies. The death rate from sepsis quickly fell to the
level seen in the midwife deliveries. The hypothesis
was successfully tested elsewhere, as mentioned
above, but communication was poor. The hypothesis
had been tested and made correct predictions. It was
immediately and resoundingly rejected."
It would take decades before doctors would wash
their hands before delivering a baby.
So where does that leave the conventional cancer
paradigm? Simply put, if we wait for the status quo to
change we shall be waiting a very long time. For
patients and families who do not have years or
decades to wait, you must become your own
advocate. There are forward thinking open-minded
physicians who can help you.
|
|
Products & Services for Patients and Professionals
|
|
Messages from Cancer Monthly Sponsors:
Cancer Foundations
Mesothelioma Research Foundation of
America - The mission of the Mesothelioma
Research Foundation of America is to fund
research that will lead to the quickest cure
for mesothelioma. Mesothelioma, a cancer of
the lining of the lungs caused by asbestos
exposure, has very few treatment options at
this time. Since the year 2001, the
foundation has funded the opening of the
Mesothelioma Laboratory under the supervision
of Dr. Parkash Gill at the USC/Norris who is
currently investigating Veglin, an
anti-angiogenesis agent. A Phase I study of
Veglin has demonstrated some success in
patients suffering from lymphoma, sarcoma,
and colon and lung cancers. Phase II studies
are on-going with the hope they will
demonstrate continued clinical efficacy in
mesothelioma and other cancers. For more
information about the Phase II study of
Veglin you may contact Dr. Gill
through the
Mesothelioma Research Foundation of America.
1-800-909-Meso (6376) http://www.mesorfa.org
Immune Boosting Products
Get Healthy Again.com - This company
provides
a variety of immune boosting nutritional
supplements
designed to enhance the immune system.
http://www.health-reports.com/cancer-
conquest.html
Polyerga® Plus - Polyerga® Plus is a
unique
nutritional supplement for supporting the immune
system. Although this German-developed spleen
peptide technology has been used in Europe
and Asia
for decades, it is only now becoming available in
America. Laboratory and clinically tested to
improve
key immune system parameters, these peptides
help to
regulate and stabilize the immune system. http://www.polyer
gaplus.com
Legal Services
Brain Cancer Misdiagnosis Information
Center
- Brain Cancer Misdiagnosis Information Center
provides information on the frequency of brain
cancer misdiagnosis, how you can find out if you
have been misdiagnosed, and what you can do about
it. The Center is run by the law firm of Webb,
Scarmozzino & Gunter. http://www.brai
ncancerlaw.com
Goldberg, Persky & White, P.C. - This law
firm (and its predecessor law firms) has been a
pioneer in asbestos litigation in the United
States.
The attorneys of Goldberg, Persky & White, P.C.
(GPW) have been involved in asbestos and
mesothelioma lawsuits since 1978. Their
experienced
mesothelioma lawyers participated in the
gathering
of evidence, such as the testimony of corporate
executives and doctors, and the accumulation of
corporate documents, that helped create the basis
for successfully suing the asbestos industry. GPW
has represented thousands of mesothelioma, lung
cancer, and asbestosis victims. Because of their
involvement in asbestos litigation from the
beginning, GPW has a clear understanding of
what is
required to succeed. In addition to outstanding
trial experience, GPW is backed by a large
arsenal
of corporate documents, depositions, and medical
articles with which to vigorously prosecute your
asbestos case. http://www.gpwlaw.
com/cm
Paul & Hanley LLP - Paul & Hanley LLP has
built its reputation
on mesothelioma-asbestos
litigation-representing individuals diagnosed
with mesothelioma or serious asbestos-related
diseases. They have an outstanding track record
of success and have garnered many of the most
significant California verdicts. Their
lawyers are known for
their honesty, integrity and compassion. They
handle a select number of cases at a time and
represent workers and families with the extra
special attention required for the best
possible outcome in each case. They understand
your case is unique, so they take the time to
get to know you and your family. Contact them
today for a free and confidential
consultation. They will discuss your specific
case and give you honest answers to your
important questions. Their toll free telephone
number is 1-800- 281-9804. They look forward to
helping you. http://www.phhlaw.com
Nutritional Support
Haelan Products offers Haelan 951, an
international award-winning, super nutritious,
fermented soybean protein beverage. Clinical
research and numerous reports from doctors and
cancer patients have demonstrated that Haelan 951
helps protect cancer patients from the toxic
side-effects of chemotherapy and radiation
treatments. In addition, one study found that the
soy isoflavone genistein (which is found in
Haelan
951) produced greater apoptosis with both
chemotherapy and radiation treatments. Apoptosis
means "programmed cell death" and it is a goal of
most orthodox cancer therapies. Because
Haelan 951
is a nutritional supplement, not a cancer
treatment,
it was used in this study to offset the
toxicity of
the treatments, not as a cancer therapy. http://www.haelan9
51.com
|
|
Your Message Seen by Thousands of Patients & Clinicians
|
|
CancerWire reaches thousands of patients and
clinicians every month who care about alternative
and integrative therapies, immune and nutritional
support, new approaches to care, and other products
and services that can genuinely improve the quality
of life of cancer patients. If you have such a
product or service we can help you get the word out.
To learn more send an e-mail to: info@cancermonthly.com
|
|
|